n
decemb
cluster
patient
pneumonia
unknown
caus
report
wuhan
china
caus
pathogen
subsequ
identifi
sever
acut
respiratori
syndromerel
newli
describ
betacoronaviru
viru
recogn
etiolog
agent
diseas
seventh
known
coronaviru
infect
human
sinc
recognit
covid
exponenti
rise
number
case
worldwid
april
world
health
organ
report
case
countri
area
territori
reason
rapid
spread
includ
high
transmiss
viru
especi
among
asymptomat
minim
symptomat
carrier
appar
absenc
crossprotect
immun
relat
viral
infect
delay
public
health
respons
measur
age
presenc
comorbid
ill
increas
risk
death
among
person
clinic
manifest
children
less
sever
compar
adult
yet
age
younger
year
seem
increas
risk
critic
ill
current
casefat
rate
estim
rang
region
seem
substanti
higher
mortal
rate
season
influenza
howev
current
estim
casefat
rate
probabl
inflat
preferenti
test
mani
countri
person
sever
manifest
risk
death
germani
south
korea
casefat
rate
less
probabl
extens
test
reveal
larg
denomin
mild
ill
estim
widescal
travel
restrict
china
undiagnos
repres
infect
sourc
document
case
observ
underscor
critic
import
ampl
accur
diagnost
test
pandem
review
current
array
test
highlight
gap
current
diagnost
capac
propos
potenti
solut
articl
includ
human
subject
publish
present
includ
articl
languag
english
french
exclud
screen
result
titl
abstract
relev
inform
start
articl
found
search
use
snowbal
search
strategi
scan
use
refer
similar
articl
retriev
consid
relev
furthermor
expert
consult
addit
literatur
guidelin
resourc
intern
organ
use
appropri
search
last
updat
april
primari
goal
epidem
contain
reduc
diseas
transmiss
reduc
number
suscept
person
popul
reduc
basic
reproduct
number
number
modul
factor
durat
viral
shed
infecti
organ
contact
matrix
infect
suscept
person
given
lack
effect
vaccin
treatment
current
avail
lever
reduc
transmiss
identifi
isol
person
contagi
deploy
test
vari
wide
across
globe
asian
countri
illustr
power
prepared
flexibl
isol
system
intens
case
find
south
korea
dramat
slow
epidem
implement
unpreced
test
effort
use
innov
measur
south
korea
perform
test
test
per
million
person
week
first
case
identifi
singapor
use
broad
case
definit
aggress
contact
trace
isol
moreov
identifi
infect
person
meet
case
definit
singapor
screen
patient
pneumonia
influenzalik
ill
hospit
primari
care
set
sever
ill
patient
intens
care
death
possibl
infecti
caus
taiwan
hong
kong
use
similar
approach
countri
rapidli
deploy
resourceintens
strategi
priorit
aggress
test
isol
interrupt
transmiss
face
widespread
transmiss
role
diagnost
test
conting
type
test
avail
resourc
requir
test
time
obtain
result
exampl
rapidli
identifi
case
among
hospit
patient
remain
high
prioriti
properli
alloc
person
protect
equip
prevent
nosocomi
spread
subsequ
commun
transmiss
likewis
specif
treatment
decis
enrol
ongo
clinic
trial
requir
prompt
diagnosi
despit
remark
speed
accur
diagnost
test
develop
made
avail
current
tool
partial
meet
sever
clinic
relev
need
figur
illustr
differ
indic
diagnost
test
among
person
proven
suspect
import
consider
clinic
decis
test
result
help
inform
test
design
must
account
sever
paramet
whether
test
detect
infect
directli
viru
indirectli
host
antibodi
test
turnaround
time
abil
perform
mani
test
time
throughput
need
minimum
number
specimen
test
batch
abil
perform
test
lowinfrastructur
set
cruis
ship
remot
commun
potenti
use
point
care
depend
test
complex
us
food
drug
administr
fda
categor
diagnost
test
complex
waiv
test
avail
use
point
care
wherea
moderateand
highcomplex
test
must
perform
laboratori
intend
use
also
determin
specimen
type
ideal
feasibl
final
import
recogn
accept
diagnost
accuraci
test
may
vari
accord
use
case
exampl
sensit
specif
requir
assay
use
confirm
result
screen
test
need
stringent
method
use
standalon
diagnosi
pool
person
test
alreadi
enrich
true
infect
foundat
innov
new
diagnost
publish
detail
assess
prioriti
use
case
consid
test
develop
policymak
respons
rapidli
evolv
pandem
countri
use
differ
test
approach
depend
test
capac
public
health
resourc
spread
viru
commun
unit
state
diagnost
test
indic
capac
limit
begin
outbreak
larg
regulatori
hurdl
use
new
test
expand
access
test
fda
releas
polici
allow
laboratori
use
valid
assay
time
manner
march
center
diseas
control
prevent
cdc
remov
restrict
test
criteria
recommend
clinician
use
judgment
determin
whether
test
perform
test
capac
remain
suboptim
implement
recommend
remain
challeng
cdc
still
recommend
prioriti
test
group
hospit
pandem
demonstr
essenti
role
diagnost
control
communic
diseas
laboratorybas
molecular
assay
detect
respiratori
specimen
current
refer
standard
diagnosi
pointofcar
technolog
serolog
immunoassay
rapidli
emerg
earli
massiv
deploy
diagnost
case
find
help
curb
epidem
sever
countri
urgent
clinic
public
health
need
drive
unpreced
global
effort
increas
test
capac
diagnost
test
patient
present
compat
symptomat
person
risk
poor
outcom
person
close
contact
someon
suspect
confirm
within
day
ill
onset
histori
travel
affect
area
patient
evalu
molecular
diagnost
test
describ
later
cdc
recommend
test
asymptomat
person
although
realtim
revers
transcriptas
polymeras
chain
reaction
rtpcr
base
assay
perform
laboratori
respiratori
specimen
cornerston
diagnost
test
sever
novel
complementari
diagnost
method
develop
evalu
figur
depict
adequaci
princip
assay
type
use
propos
key
use
case
among
patient
diagnos
occurr
concomit
viral
infect
report
rang
greater
result
possibl
rule
infect
mere
detect
anoth
respiratori
pathogen
current
diagnost
strategi
recommend
cdc
identifi
patient
test
sampl
taken
respiratori
tract
assess
presenc
sever
nucleic
acid
target
specif
nasopharyng
specimen
prefer
choic
swabbas
test
oropharyng
midturbin
anterior
nare
sampl
also
accept
sampl
obtain
use
flock
swab
avail
enhanc
collect
releas
cellular
materi
swab
aluminum
plastic
shaft
prefer
swab
contain
calcium
algin
wood
cotton
avoid
may
contain
substanc
inhibit
pcr
test
ideal
swab
transfer
univers
transport
medium
immedi
sampl
collect
preserv
viral
nucleic
acid
sampl
taken
sputum
endotrach
aspir
bronchoalveolar
lavag
also
may
sent
directli
microbiolog
laboratori
process
may
greater
sensit
upper
respiratori
tract
specimen
inadequ
sampl
collect
may
result
falseneg
test
specimen
collect
sampl
undergo
rna
extract
follow
qualit
rtpcr
target
detect
unit
state
cdc
develop
wide
use
assay
kit
contain
pcr
primerprob
set
region
viral
nucleocapsid
gene
human
rnase
p
gene
ensur
rna
extract
success
assay
differ
world
health
organ
primerprob
set
target
rnadepend
rna
polymeras
rdrp
envelop
e
gene
assay
high
analyt
sensit
specif
minim
crossreact
circul
strain
coronavirus
use
cycl
threshold
less
criterion
posit
cdc
kit
may
use
state
public
health
laboratori
laboratori
determin
state
qualifi
clinic
laboratori
meet
regulatori
requir
test
well
suit
one
use
case
epidemiolog
surveil
may
complet
inadequ
anoth
rapid
screen
symptomat
patient
alloc
person
protect
equip
test
result
enabl
specif
clinic
decis
test
develop
policymak
clinician
need
consid
respect
intent
test
popul
test
specif
possibl
moment
use
case
place
green
gray
bar
best
met
nucleic
acid
amplif
test
wherea
detect
hostderiv
antibodi
direct
crucial
surveil
epidem
forecast
determin
immun
sever
acut
respiratori
syndromerel
clinic
laboratori
improv
amend
clia
perform
highcomplex
test
dozen
laboratori
appli
emerg
use
author
eua
fda
laboratorydevelop
assay
fda
also
grant
eua
sever
commerci
assay
expand
abil
clinic
laboratori
use
platform
tabl
lack
establish
refer
standard
use
differ
sampl
collect
prepar
method
incomplet
understand
viral
dynam
across
time
cours
infect
hamper
rigor
assess
diagnost
accuraci
mani
newli
introduc
assay
serum
urin
usual
neg
presenc
viral
nucleic
acid
regardless
ill
sever
import
abil
rtpcr
assay
rule
basi
upper
respiratori
tract
sampl
obtain
singl
time
point
remain
unclear
convers
patient
posit
test
result
sever
author
recommend
obtain
least
neg
upper
respiratori
tract
sampl
collect
interv
hour
longer
document
clearanc
lowcomplex
rapid
result
within
hour
molecular
diagnost
test
respiratori
viral
infect
clia
waiv
fda
approv
use
outsid
laboratori
nonlaboratori
personnel
includ
cartridgebas
assay
platform
includ
abbott
id
abbott
laboratori
biofir
filmarray
rieux
coba
liat
roch
diagnost
genexpert
cepheid
rapid
pointofcar
assay
instrument
critic
expand
pointofcar
test
xpert
xpress
test
cepheid
receiv
fda
eua
perform
genexpert
platform
alreadi
wide
use
tuberculosi
hiv
test
especi
lowand
middleincom
countri
capac
might
use
scale
test
across
world
well
set
rapid
result
point
care
would
medium
green
cell
current
avail
tool
well
adapt
intend
use
within
use
case
term
diagnost
accuraci
format
turnaround
time
light
green
cell
assay
avail
project
short
term
use
import
limit
use
exampl
current
rtpcr
assay
may
yield
falseneg
result
person
incub
phase
low
viral
load
dark
green
cell
assay
type
meet
need
use
case
naat
nucleic
acid
amplif
test
poc
point
care
rtpcr
revers
transcriptas
polymeras
chain
reaction
assum
assay
develop
current
undergo
regulatori
evalu
prove
accur
util
antibodi
detect
assay
diagnos
acut
infect
probabl
limit
around
time
symptom
onset
viral
shed
transmiss
risk
seem
highest
thu
although
test
may
role
among
person
present
late
cours
infect
potenti
misus
high
diagnost
test
enabl
clinic
decis
although
test
throughput
may
limit
factor
test
detect
respiratori
syncyti
viru
influenza
viru
antigen
immunoassay
directli
clinic
specimen
commerci
avail
decad
low
complex
may
provid
result
within
minut
point
care
current
tool
influenza
respiratori
syncyti
viru
suffer
suboptim
sensit
rule
diseas
challeng
would
probabl
exist
test
would
need
implement
clear
guidanc
correct
interpret
prototyp
test
novel
coronavirus
receiv
regulatori
approv
develop
monoclon
antibodi
nucleocapsid
protein
gener
might
form
basi
futur
rapid
antigen
detect
test
serolog
test
identifi
antibodi
iga
igm
igg
clinic
specimen
blood
saliva
enzymelink
immunosorb
assay
may
less
complex
molecular
test
potenti
use
diagnosi
certain
situat
howev
util
diagnos
acut
infect
probabl
limit
around
time
symptom
onset
viral
shed
transmiss
risk
seem
highest
antibodi
respons
infect
take
day
week
reliabl
neg
result
would
exclud
infect
particularli
among
recent
exposur
viru
crossreact
antibodi
coronaviru
protein
also
potenti
problem
wherebi
posit
result
may
result
past
present
infect
human
coronavirus
serolog
assay
might
relev
scenario
patient
present
medic
care
late
complic
diseas
rtpcr
may
fals
neg
viral
shed
drop
time
develop
serolog
assay
accur
assess
prior
infect
immun
essenti
epidemiolog
studi
ongo
surveil
vaccin
studi
potenti
risk
assess
health
care
worker
immunoassay
alreadi
market
countri
diagnost
accuraci
optim
use
remain
undefin
optim
use
diagnost
imag
biomark
nonmicrobiolog
test
rapidli
evolv
mani
center
evalu
util
chest
imag
diagnosi
chest
radiographi
bilater
pneumonia
frequent
report
featur
rang
common
unilater
focu
comput
tomographi
regard
sensit
radiographi
sever
cohort
studi
report
patient
ground
glass
opac
featur
commonli
report
chest
comput
tomographi
includ
peripher
distribut
fine
reticular
opac
vascular
thicken
compar
serial
nasopharyng
sampl
chest
comput
tomographi
may
sensit
rtpcr
test
singl
time
point
diagnosi
addit
artifici
intellig
may
help
distinguish
etiolog
agent
communityacquir
pneumonia
howev
find
complet
specif
exclud
coinfect
altern
diagnosi
common
laboratori
featur
report
patient
includ
decreas
albumin
ci
elev
creactiv
protein
ci
elev
lactat
dehydrogenas
level
ci
lymphopenia
ci
biomark
report
includ
increas
erythrocyt
sediment
rate
elev
aspart
aminotransferas
alanin
aminotransferas
creatinin
kinas
level
leukopenia
leukocytosi
increas
bilirubin
creatinin
level
find
surpris
biomark
repres
inflammatori
host
respons
earli
marker
endorgan
dysfunct
similar
seen
patient
sepsi
biomark
combin
biomark
current
exist
sensit
specif
enough
establish
diagnosi
pragmat
predict
clinic
cours
face
public
health
emerg
import
first
step
expand
test
capac
includ
relax
streamlin
regulatori
requir
procedur
local
public
health
laboratori
academ
diagnost
laboratori
unit
state
rapidli
enabl
perform
euagrant
commerci
assay
laboratorydevelop
test
use
research
useonli
reagent
univers
research
laboratori
could
also
add
capac
although
concern
exist
regard
qualiti
control
absenc
protocol
manag
clinic
specimen
flexibl
regard
nucleic
acid
extract
method
amplif
instrument
use
cdc
protocol
introduc
nation
agenc
expediti
make
materi
test
develop
valid
avail
clinic
laboratori
diagnost
test
manufactur
safe
evalu
clinic
stabl
person
tradit
health
care
access
point
resourc
intens
slow
risk
expos
staff
infect
mani
jurisdict
enabl
innov
test
venu
extern
tent
drivethrough
phone
booth
test
well
home
assess
team
expedit
specimen
collect
limit
potenti
exposur
telemedicin
combin
athom
nasal
swab
selftest
also
propos
import
jurisdict
without
univers
health
care
coverag
polici
solut
must
introduc
elimin
financi
barrier
test
uninsur
underinsur
patient
effort
increas
access
test
multipl
use
case
need
coupl
appropri
public
health
intervent
isol
infect
person
contact
nasopharyng
swab
recommend
specimen
molecular
analysi
sudden
demand
flock
nasopharyng
swab
viral
transport
medium
gener
pandem
put
enorm
pressur
suppli
chain
capac
product
march
cdc
made
oropharyng
midturbin
nasal
swab
accept
specimen
type
nasopharyng
swab
avail
earlymorn
posterior
oropharyng
saliva
sampl
cough
clear
throat
also
assess
use
specimen
type
would
requir
use
swab
cdc
releas
standard
oper
procedur
laboratori
creat
viral
transport
medium
solut
also
may
use
viral
transport
medium
unavail
includ
phosphatebuff
salin
liquid
ami
normal
salin
fda
provid
review
diagnost
test
guidanc
web
site
altern
materi
collect
transport
sampl
rtpcr
assay
diagnost
valu
molecular
test
nonrespiratori
specimen
current
unclear
although
excel
tool
exist
diagnosi
symptomat
patient
wellequip
laboratori
import
gap
remain
screen
asymptomat
person
incub
phase
well
accur
determin
live
viral
shed
among
patient
convalesc
phase
inform
deisol
decis
figur
critic
advanc
solut
requir
less
wellequip
laboratori
curb
pandem
global
foundat
innov
new
diagnost
find
other
creat
onlin
resourc
collat
rapidli
evolv
set
assay
variou
stage
develop
proof
concept
full
regulatori
approv
simpl
antigenbas
test
sensit
enough
might
use
lowerresourc
home
set
inform
quarantin
spatial
distanc
measur
patient
without
sever
ill
contact
novel
technolog
cluster
regularli
interspers
short
palindrom
repeat
crispr
base
diagnost
use
develop
rapid
simpl
lowcost
portabl
temperaturest
assay
deploy
field
nontradit
resourcelimit
set
airport
border
cross
technolog
might
deploy
lowerresourc
set
standard
exampl
might
possibl
leverag
exist
loopmedi
isotherm
amplif
test
network
establish
diseas
human
african
trypanosomiasi
surveil
critic
consider
diagnost
use
epidem
diseas
public
health
import
includ
qualiti
assur
regulatori
framework
surround
test
matur
regulatori
agenc
develop
mechan
account
emerg
fda
eua
stream
pragmat
solut
must
found
facilit
widescal
independ
evalu
emerg
test
initi
need
elabor
biosafeti
precaut
inconsist
recommend
applic
across
region
sever
hamper
test
although
continu
evolv
current
recommend
canada
unit
state
acknowledg
nonpropag
work
molecular
test
may
perform
contain
level
condit
found
routin
diagnost
laboratori
provid
specif
guidanc
diagnost
test
specimen
conduct
outsid
biosafeti
level
laboratori
rapid
respiratori
test
perform
point
care
pandem
dramat
highlight
essenti
role
diagnost
control
communic
diseas
intens
diagnost
deploy
probabl
contribut
success
countri
control
transmiss
urgent
clinic
public
health
need
drive
unpreced
global
effort
increas
test
capac
final
blind
speed
spread
illustr
need
prepared
longterm
invest
diagnost
test
disclosur
dr
cheng
report
grant
canadian
institut
health
research
mcgill
interdisciplinari
initi
infect
immun
conduct
studi
manuscript
written
submit
offer
posit
scientif
advisori
board
lifesci
posit
unrel
submit
work
dr
papenburg
report
grant
person
fee
bd
diagnost
seegen
abbvi
person
fee
cepheid
grant
medimmun
sanofi
pasteur
janssen
pharmaceut
hoffmanla
roch
outsid
submit
work
dr
kanjil
report
grant
phast
diagnost
outsid
submit
work
dr
libman
report
grant
geosentinel
network
outsid
submit
work
dr
yansouni
report
nonfinanci
support
rieux
outsid
submit
work
author
name
disclos
conflict
interest
disclosur
also
view
wwwacponlineorgauthorsicmjeconflictofinterestform
